These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 22095009)

  • 1. Etiopathogenetic principles and peptic ulcer disease classification.
    Tytgat GN
    Dig Dis; 2011; 29(5):454-8. PubMed ID: 22095009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
    Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
    Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals.
    Brzozowski T; Konturek PC; Sliwowski Z; Kwiecień S; Drozdowicz D; Pawlik M; Mach K; Konturek SJ; Pawlik WW
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():67-79. PubMed ID: 17033106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental production of peptic ulcer, gastric damage and cancer models and their use in pathophysiological studies and pharmacological treatment--Polish achievements.
    Brzozowski T
    J Physiol Pharmacol; 2003 Dec; 54 Suppl 3():99-126. PubMed ID: 15075467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
    Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
    Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical issues in the pathophysiology and management of peptic ulcer disease.
    Hunt RH; Malfertheiner P; Yeomans ND; Hawkey CJ; Howden CW
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):685-99. PubMed ID: 8590166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy.
    Lanas A; Remacha B; Sáinz R; Hirschowitz BI
    Am J Gastroenterol; 2000 Feb; 95(2):513-9. PubMed ID: 10685760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of patients with gastric outlet obstruction related to peptic ulcer disease treated with endoscopic balloon dilatation and drug therapy.
    Cherian PT; Cherian S; Singh P
    Gastrointest Endosc; 2007 Sep; 66(3):491-7. PubMed ID: 17640640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds.
    Scarpignato C; Pelosini I
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S63-72. PubMed ID: 10379472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Historical impact to drive research in peptic ulcer disease.
    Banić M; Malfertheiner P; Babić Z; Ostojić R; Kujundzic M; Fatović-Ferenčić S; Plesko S; Petričušić L
    Dig Dis; 2011; 29(5):444-53. PubMed ID: 22095008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptic ulcer disease today.
    Yuan Y; Padol IT; Hunt RH
    Nat Clin Pract Gastroenterol Hepatol; 2006 Feb; 3(2):80-9. PubMed ID: 16456574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of peptic ulcer disease and current trends in therapy.
    Desai JK; Goyal RK; Parmar NS
    Indian J Physiol Pharmacol; 1997 Jan; 41(1):3-15. PubMed ID: 10225026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in gastric and duodenal ulcers.
    Venerito M; Malfertheiner P
    Helicobacter; 2010 Aug; 15(4):239-50. PubMed ID: 20633184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs.
    Quan C; Talley NJ
    Am J Gastroenterol; 2002 Dec; 97(12):2950-61. PubMed ID: 12492176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Peptic ulcer, Helicobacter pylori].
    Bauerfeind P; Wirth HP
    Ther Umsch; 1997 Nov; 54(11):624-8. PubMed ID: 9454363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Causal role of Helicobacter pylori in peptic ulcer relapse.
    Asaka M; Ohtaki T; Kato M; Kudo M; Kimura T; Meguro T; Horita S; Inoue K
    J Gastroenterol; 1994 Jul; 29 Suppl 7():134-8. PubMed ID: 7921146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users].
    Shimada T; Yamagata M; Hiraishi H
    Nihon Rinsho; 2007 Oct; 65(10):1824-9. PubMed ID: 17926531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Helicobacter pylori in peptic ulcer and gastric cancer].
    Matsukura N; Onda M; Yamashita K
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):169-78. PubMed ID: 7857088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An etiologic approach to management of duodenal and gastric ulcers.
    Rex DK
    J Fam Pract; 1994 Jan; 38(1):60-7. PubMed ID: 8289053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helicobacter pylori and its involvement in gastritis and peptic ulcer formation.
    Konturek SJ; Konturek PC; Konturek JW; Plonka M; Czesnikiewicz-Guzik M; Brzozowski T; Bielanski W
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():29-50. PubMed ID: 17033104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.